MEK inhibitors for the treatment of NRAS mutant melanoma.

Publication/Presentation Date

1-1-2018

Abstract

Melanoma is increasing rapidly in incidence and prevalence, especially in younger females and older males. Treatment options have expanded beyond high-dose interleukin 2 and adoptive T-cell therapy to include inhibitors of immune checkpoints programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and small molecular inhibitors of pathways activated in melanoma, in particular the mitogen-activated protein kinase (MAPK) pathway. PD-1/CTLA-4 inhibitors and inhibitors of MAPK such as BRAF/MEK inhibitors have significantly improved survival in both the metastatic and, more recently, adjuvant settings. In this review, we discuss the preclinical data, clinical development, and potential use of novel MEK inhibitor binemetinib, particularly in the setting of

Volume

12

First Page

2553

Last Page

2565

ISSN

1177-8881

Disciplines

Medicine and Health Sciences

PubMedID

30154648

Department(s)

Fellows and Residents

Document Type

Article

Share

COinS